Download PDF
Thromb Haemost 2000; 84(01): 1-3
DOI: 10.1055/s-0037-1613957
Commentary
Schattauer GmbH

Renewed Interest in Haemostasis Changes Induced by Oral Contraceptives (OCs)

C. Kluft
1   From the Gaubius Laboratory, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Publication Date:
10 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Gaspard U, Jespersen J, Kluft C, Mattson L-A, Samsioe G, Skouby SO. Consensus development meeting: metabolic aspects of oral contraceptives of relevance for cardiovascular diseases. Am J Obstet Gynecol 1990; 162: 1335-7.
    CrossrefPubMedGoogle Scholar
  • 2 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
    CrossrefPubMedGoogle Scholar
  • 3 World Health Organization Collaborative Study of Cardiovascular disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case control study. Lancet 1995; 346: 1575-82.
    CrossrefPubMedGoogle Scholar
  • 4 Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Transnational Research Group on Oral Contraceptives and Health of Young Women. Br Med J 1996; 312: 83-8.
    CrossrefPubMedGoogle Scholar
  • 5 Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
    CrossrefPubMedGoogle Scholar
  • 6 Vandenbroucke JP. Epidemiology – Annotation of Esbjerg I consensus meeting. Gynecol Endocrinol 1996; 10 (Suppl. 02) 5-7.
    PubMedGoogle Scholar
  • 7 The Oral Contraceptive and Haemostasis Study Group. An open label, randomized study to evaluate the effects of seven monophasic oral contraceptive regimen on haemostatic variables. Contraception 1999; 59: 345-55.
    CrossrefPubMedGoogle Scholar
  • 8 Tans G, Curvers J, Middeldorp S, Thomassen MCLGD, Meijers JCM, Prins MH, Bouma BN, Büller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 84: 15-21.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Meijers JCM, Middeldorp S, Tekelenburg W, Van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XIindependent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 84: 9-14.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Middeldorp S, Meijers JCM, Van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Büller HR. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a crossover study. Thromb Haemost 2000; 84: 4-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Rosing J, Middeldorp S, Curvers J, Thomassen MCLGD, Nicolaes GAF, Meijers JCM, Bouma BN, Buller HR, Prins MH, Tans G. Acquired APC resistance and oral contraceptives: A randomized cross-over study of two low dose oral contraceptives. Lancet 1999; 354: 2036-40.
    CrossrefPubMedGoogle Scholar
  • 12 Winkler UH. Effects on hemostatic variables of desogestrel- and gestodenecontaining oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: A review. Am J Obstet Gynecol 1998; 179: S51-S61.
    CrossrefPubMedGoogle Scholar
  • 13 Kluft C. Effects on haemostasis variables by second and third generation combined oral contraceptives: a review of directly comparative studies. Curr Med Chem 2000; 07: 585-9.
    CrossrefPubMedGoogle Scholar
  • 14 Kluft C, Lansink M. Effect of oral contraceptives on haemostatic variables. Thromb Haemost 1997; 78: 315-26.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Koster T, Rosendaal FR, Reitsma PH, van der velden PA, Briet E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms – the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994; 71: 719-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Kamphuisen PW, Rosendaal FR, Eikenboom JCJ, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V Leiden and relation with factor VIII:ag levels. Thesis, Leiden University; The Netherlands: 2000: 75-88.
  • 17 Liberti G, Bertina RM, Rosendaal FR. Hormonal state rather than age influence cut-off values of protein S; reevaluation of the thrombotic risk associated with protein S deficiency. Thromb Haemost 1999; 82: 1093-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA, Thijssen JH. Effects of seven low dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990; 41: 345-52.
    CrossrefPubMedGoogle Scholar
  • 19 Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375-81.
    CrossrefPubMedGoogle Scholar
  • 20 Kluft C, de Maat MP, Heinemann LA, Spannagl M, Schramm W. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation. Lancet 1999; 354: 832-3.
    CrossrefPubMedGoogle Scholar
  • 21 Rosing J, Tans G, Nicolaes GAF, Thomassen GAF, van Oerle R, van der Ploeg PMEN, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haemat 1997; 97: 233-8.
    CrossrefPubMedGoogle Scholar
  • 22 Curvers J, Thomassen MCLGD, Nicolaes GAF, van Oerle R, Hamulyak K, Hemker HC, Tans G, Rosing J. Acquired APC resistance and oral contraceptives: differences between two functional tests. Br J Haematol 1999; 105: 88-94.
    CrossrefPubMedGoogle Scholar
  • 23 Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and monitoring of anticoagulant therapy. Semin Thromb Hemost 1999; 25: 407-18.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Heinemann LAJ, Assmann A, Spannagl M, Schramm W, Dick A, Kluft C, de Maat MPM. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism. Contraception 1998; 58: 321-2.
    CrossrefPubMedGoogle Scholar
  • 25 Tans G, Rosendaal FR, Curvers J, Thomassen MCLGD, Bertina RM, Rosing J. APC resistance determined with the endogenous thrombin generation potential is associated with venous thrombosis: a blinded clinical evaluation. Thromb Haemost 1999; supplement: abstract 640: 202-3.
    PubMedGoogle Scholar
  • 26 Reproductive choices in 2000: The relative safety of current oral contraceptives. Cohen J, Edwards RG. (eds) Hum. Reprod. Update 1999; 05: 563-75.
    CrossrefPubMedGoogle Scholar
  • 27 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing thirdgeneration progestagen. Lancet 1995; 346: 1593-6.
    CrossrefPubMedGoogle Scholar
  • 28 Perez SGutthann, Garcia LARodriguez, Castellsague J, Duque AOliart. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. Brit Med J 314: 796-800.
    PubMedGoogle Scholar